Browse the evidence

Peri-exercise caffeine, nitrate-containing supplements, and sodium bicarbonate can enhance aspects of endurance performance.

Athletes may benefit from these supplements to improve endurance performance.

Behavioral treatment for obesity includes components such as self-monitoring, functional analyses, stimulus control, cognitive restructuring, problem-solving, and relapse prevention.

Practitioners should incorporate these components into obesity treatment programs.

Weight loss requires the induction of a negative energy balance.

Weight loss strategies should focus on creating a negative energy balance.

Patient-delivered lifestyle intervention yielded significantly less weight regain than standard-of-care (SOC) at month 18 (0.77 kg vs 2.37 kg; P = .002).

Patient-delivered interventions may be a viable alternative for weight loss maintenance.

Patient-delivered intervention showed parallel improvements in diastolic blood pressure, heart rate, physical activity, and sedentary behavior compared to SOC.

Improving cardiovascular metrics can enhance overall health in weight maintenance programs.

Both intermittent fasting (IF) and ketogenic diet (KD) independently show clinically significant benefits in improving metabolic parameters in metabolic syndrome (MetS) and type 2 diabetes (T2D), including reductions in HbA1c, fasting glucose, body weight, and triglycerides.

Practitioners may consider IF and KD as effective dietary interventions for managing MetS and T2D.

Competitors generally adjusted resistance training (RT) in a variety of ways during peak week, with proximity-to-failure being the most frequently manipulated variable.

Trainers should consider adjusting training variables like proximity-to-failure for competitors during peak week.

During peak week, frequency, volume, and intensity of resistance training decreased while repetition ranges of compound exercises increased.

Competitors should focus on adjusting their training load to reduce stress while increasing repetitions for compound movements.

Each 100 MET-min/wk increase in accelerometry-measured moderate-to-vigorous physical activity (MVPA) from baseline to 4 years is associated with decreased risk of cardiovascular disease (CVD) outcomes.

Encouraging long-term engagement in MVPA can help reduce CVD risk in this population.

Increased accelerometry-measured MVPA from baseline to year 4 is associated with decreased risk of CVD outcomes.

Long-term engagement in MVPA is crucial for reducing CVD risk in this demographic.

A maintenance dose of 1.2 g·d-1 of beta-alanine (BA) was effective in maintaining performance during repeated sprints.

Practitioners can consider a lower maintenance dose of beta-alanine to sustain performance in repeated sprint activities.

Among individuals with central adiposity, replacing SSB with either ASB or USB had a favorable effect on body weight.

Practitioners may consider recommending ASB or USB for weight management in individuals with central adiposity.

Use of GLP‐1 or GLP‐1/GIP RA therapy after lung transplantation was effective at decreasing weight and improving hemoglobin A1c.

Practitioners can consider GLP-1 and GLP-1/GIP RA therapies for weight management and glycemic control in lung transplant patients.

Semaglutide led to a mean relative weight loss of 13.3 ± 11.3% after 12 months in adults with type 1 diabetes.

Practitioners can consider semaglutide as an effective option for weight management in overweight/obese patients with type 1 diabetes.

The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) decreased from 82.6% to 30.4% after treatment with semaglutide.

Semaglutide may significantly improve liver health in patients with type 1 diabetes and MASLD.

Adding semaglutide to usual care in US adults without diabetes is projected to avert 358,400 major adverse cardiovascular events (MACE) at a cost of $148,100 per quality-adjusted life-year (QALY) gained.

Semaglutide may be a beneficial addition to treatment plans for eligible patients to reduce cardiovascular risks.

Lifestyle intervention combined with older obesity medications is associated with approximately 5%-10% weight loss.

Combining lifestyle changes with medications can enhance weight loss outcomes for patients.

GLP-1 analogs have shown efficacy in improving weight loss and cardiovascular risk factors.

Practitioners may consider GLP-1 analogs as a treatment option for weight management in menopausal women.

Initiation of semaglutide was significantly associated with a -3.8% reduction in weight at 13 to 24 months.

Semaglutide may be an effective option for weight management in adults.

Patients can achieve significant weight reduction with the fixed-dose, extended-release combination of naltrexone and bupropion (NB-ER) compared with placebo when combined with a reduced-calorie diet and increased physical activity.

Practitioners should consider prescribing NB-ER for patients with obesity who are also engaging in dietary and physical activity changes.

The appropriate use of NB-ER should consider the specific characteristics and adiposity-related complications of an individual.

Practitioners should assess individual patient characteristics when prescribing NB-ER.

Gewichtsreduktion senkt die Konversion eines Prädiabetes in einen Typ-2-Diabetes um 58 % durch Lebensstilintervention.

Praktiker sollten Lebensstilinterventionen zur Gewichtsreduktion empfehlen, um das Risiko für Typ-2-Diabetes zu senken.

Eine Gewichtsreduktion von 10 kg senkt die Gesamtmortalität bei Menschen mit Typ-2-Diabetes um 25 %.

Gewichtsreduktion sollte als Strategie zur Verbesserung der Lebensdauer bei Diabetikern gefördert werden.

Eine Gewichtsreduktion verbessert Blutzuckerwerte und nahezu alle Komorbiditäten des Diabetes.

Ärzte sollten Gewichtsreduktion als Teil der Behandlung von Diabetes und seinen Komorbiditäten empfehlen.